PLCG1 and cancer: In the cell cycle pathway, GSK3B, CDK2, and CDK1 are reduced by cisplatin in each cell line, and in cancer pathways, cisplatin reduces phosphorylation of GSK3B, AKT1, PDGFRa/b, PLCG1/2, and CDK2.